Targeted Radiotherapy
About us
- Team
- Contact
- Directions
News
Careers
Search
Menu Menu

Blog - Latest News

You are here: Home1 / 20232 / 3B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for...

24. April 2023/by imken

3B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology

Share this entry

Share on Facebook
Share on Twitter
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png 0 0 imken https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png imken2023-04-24 11:43:472023-04-24 11:46:523B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology

© 3B Pharmaceuticals
Imprint
Data privacy statement

3B Pharmaceuticals GmbH
Magnusstraße 11
D-12489 Berlin
Tel: +49 (0)30 / 63 92 - 43 17
Fax: +49 (0)30 / 63 92 - 43 16
info@3b-pharma.com

3BP company statement re recent events involving Clovis Oncology and FAP-22...RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals...